AlloSource earns laser etching patent: 3 notes

AlloSource received a U.S. patent for its proprietary method to create ProChondrixCR, the company’s fresh cryopreserved osteochondral allograft.  

Advertisement

Here are three things to know:

1. The patent, titled “Enclosure for laser cutting of human tissue,” includes AlloSource’s process of producing a closed system that allows a laser beam to pass through and etch allograft tissue while maintaining a sterile barrier.

2. The method is designed to expedite processing, maximize tissue use and allow for the use of a specialized laser technology in a clean room setting.

3. ProChondrixCR is a cartilage restoration therapy. “Laser etching stimulates the cartilage regenerative system while the graft replaces the missing cartilage in superficial defects down to the bone level,” said AlloSource Senior Medical Director Ross Wilkins, MD.

More articles on biologics:
4 things to know about Bio2 Technologies
Spine biologics market to reach $2.72B by 2025 — 3 things to know
Vail-Summit Orthopaedics uses injectable treatments, biologics to expand care: 3 notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Is ambulatory care healthcare’s big margin engine? 4 leaders weigh in

Wednesday, July 29
1:00 PM - 2:00 PM CDT

Presenters: Joe Ganley, athenahealthJeffrey Flynn, CASC, Gramercy Surgery CenterBryan Tsao, Access Center, Loma Linda University HealthJason Zepeda, Northridge Hospital Medical Center, CommonSpirit HealthGreg DeConciliis, PA-C, CASC, Boston Out­Patient Surgical Suites

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.